Press Releases
-
Dec 9, 2017
Valoctocogene Roxaparvovec Demonstrated Sustained Normal or Near Normal Factor VIII Levels in Severe Hemophilia A for Most Patients at Both Doses in Phase 1/2 StudyBioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today an update to its previously reported results of an open-label Phase 1/2 study of valoctocogene roxaparvovec (formerly BMN 270), an...
-
Dec 6, 2017Oral Presentation to Include 78 Week Data with 6e13 Dose Cohort and 32 Week Data with 4e13 Dose Cohort from its Ongoing Phase 1/2 valoctocogene roxaparvovec (formerly BMN 270) Clinical Program, a Gene Therapy for Hemophilia A
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that the company will present data in a late breaking abstract session at the 59th American Society of Hematology (ASH) Annual Meeting &...
-
Nov 27, 2017
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that it has entered into a definitive agreement to sell the Rare Pediatric Disease Priority Review Voucher (PRV) it obtained in April of...
-
Oct 31, 2017- Credit Suisse's 26th Annual Healthcare Conference on November 7 in Scottsdale, AZ
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will participate in Credit Suisse's 26th Annual Healthcare Conference on November 7, 2017 at 9:10am MT/11:10am ET, in...
-
Oct 26, 2017- Company Announces Total Revenues of $334.1 million in the Third Quarter of 2017; Full-year Revenue Guidance Confirmed at between $1.29 billion and $1.32 billion
Financial Highlights (in millions of U.S. dollars, except per share data, unaudited) Three Months Ended September 30, Nine Months Ended September 30, 2017 2016 % Change 2017 2016 % Change Total...
